Published in Drug Week, January 5th, 2007
The indication also includes the following qualifying statement that "patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination." The expanded indication is based on phase III results that demonstrate a survival advantage by using Hycamtin (0.75 mg/m2 days 1-3) in combination with cisplatin (50...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.